Regenerative Medicine Peptides: The 2026 Category Matrix
Regenerative medicine peptides cover far more than the popular BPC-157 vs TB-500 debate. This 2026 matrix maps five major peptide classes, clarifying FDA approval, Category 2 delisting, and compounding eligibility amid a pivotal year of regulatory change.
Stem Cell Therapy for Hair Regrowth: How Much Density Can You Expect?
Curious what stem cell therapy for hair regrowth can really deliver? This article breaks down clinical data on hair count and density gains across ADSC, SVF, and exosome treatments, plus a realistic month-by-month timeline for results.
Alliance for Regenerative Medicine: Decoding the 2026 Data
The Alliance for Regenerative Medicine’s 2026 State of the Industry data offers a critical lens into cell and gene therapy’s growth, from five commercial blockbusters to a sharp rise in FDA Complete Response Letters. This article breaks down what ARM’s key metrics mean for investors, analysts, and anyone tracking the CGT pipeline.